Euro-Med Laboratories Phil., Inc. (PSE:EURO)
Philippines · Delayed Price · Currency is PHP 1.160
0.00 (0.00%)
At close: Oct 7, 2026
PSE:EURO Ratios and Metrics
Market cap in millions PHP. Fiscal year is January - December.
Millions PHP. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,770 | 4,112 | 3,372 | 3,084 | 3,578 | 5,757 | |
Market Cap Growth | 24.73% | 21.95% | 9.33% | -13.79% | -37.86% | -40.17% |
Enterprise Value | 7,159 | 7,158 | 6,436 | 6,159 | 6,427 | 8,754 |
Last Close Price | 1.16 | 1.00 | 0.77 | 0.66 | 0.73 | 1.13 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 9.67 | 8.74 | 9.99 | 10.64 | 17.90 | 34.06 |
PS Ratio | 0.69 | 0.60 | 0.58 | 0.59 | 0.85 | 1.61 |
PB Ratio | 0.76 | 0.68 | 0.57 | 0.53 | 0.63 | 1.02 |
P/TBV Ratio | 0.79 | 0.71 | 0.60 | 0.55 | 0.66 | 1.07 |
P/FCF Ratio | 5.73 | 5.85 | 66.47 | 49.54 | 60.28 | 28.38 |
P/OCF Ratio | 4.72 | 4.24 | 13.66 | 8.71 | 24.14 | 11.79 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.03 | 1.04 | 1.11 | 1.17 | 1.52 | 2.44 |
EV/EBITDA Ratio | 5.47 | 5.84 | 6.93 | 6.92 | 9.68 | 13.70 |
EV/EBIT Ratio | 7.68 | 7.96 | 9.62 | 9.44 | 14.59 | 21.30 |
EV/FCF Ratio | 8.60 | 10.19 | 126.86 | 98.92 | 108.29 | 43.16 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.64 | 0.71 | 0.73 | 0.69 | 0.65 | 0.61 |
Debt / EBITDA Ratio | 3.07 | 3.32 | 4.30 | 4.25 | 5.06 | 4.96 |
Debt / FCF Ratio | 4.83 | 6.14 | 84.62 | 64.87 | 62.02 | 16.87 |
Net Debt / Equity Ratio | 0.38 | 0.46 | 0.54 | 0.51 | 0.50 | 0.48 |
Net Debt / EBITDA Ratio | 1.93 | 2.28 | 3.45 | 3.32 | 4.33 | 4.22 |
Net Debt / FCF Ratio | 2.87 | 3.98 | 63.11 | 47.47 | 48.44 | 13.28 |
Asset Turnover | 0.63 | 0.62 | 0.53 | 0.51 | 0.43 | 0.36 |
Inventory Turnover | 2.73 | 2.67 | 2.20 | 2.09 | 1.95 | 1.62 |
Quick Ratio | 1.03 | 0.91 | 0.78 | 0.71 | 0.69 | 0.71 |
Current Ratio | 1.57 | 1.47 | 1.36 | 1.31 | 1.33 | 1.33 |
Return on Equity (ROE) | 8.29% | 7.87% | 5.76% | 5.02% | 3.52% | 3.05% |
Return on Assets (ROA) | 5.31% | 5.09% | 3.85% | 3.92% | 2.79% | 2.60% |
Return on Invested Capital (ROIC) | 8.01% | 7.40% | 5.78% | 5.46% | 3.71% | 3.61% |
Return on Capital Employed (ROCE) | 12.40% | 12.30% | 9.50% | 9.50% | 6.50% | 6.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 10.70% | 11.44% | 10.01% | 9.40% | 5.59% | 2.94% |
FCF Yield | 17.45% | 17.09% | 1.50% | 2.02% | 1.66% | 3.52% |
Dividend Yield | 6.03% | - | 9.12% | 9.15% | 4.81% | 1.77% |
Payout Ratio | 56.37% | 61.21% | 73.07% | 49.64% | 72.00% | - |
Total Shareholder Return | 6.03% | - | 9.12% | 9.15% | 4.81% | 1.77% |